Enabling Selectivity: Visualizing What Counts

Over 60,000 patient exposures in 41 countries (excluding the U.S.) have had tumor resections enhanced by the use of Gleolan. NXDC’s new drug application with the FDA was approved in June 2017 with a commercial launch expected during the first half of 2018. Today over 90 prominent neurosurgeons have completed the necessary training to use Gleolan and fluorescent guided surgery with the goal of improving their patient outcomes.